Differenze

Queste sono le differenze tra la revisione selezionata e la versione attuale della pagina.

Link a questa pagina di confronto

Entrambe le parti precedenti la revisione Revisione precedente
Prossima revisione
Revisione precedente
aree:proteomica:rppa:bibliografia [2017/02/16 21:20]
Gianluca Frustagli
aree:proteomica:rppa:bibliografia [2017/02/18 22:41] (versione attuale)
Gianluca Frustagli
Linea 13: Linea 13:
  
 Signore M et al. \\ Signore M et al. \\
-UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response. \\+[[https://​www.ncbi.nlm.nih.gov/​pubmed/​27286453|UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response.]] \\
 <wrap lo>​Oncotarget. 2016 Jul 12;​7(28):​44113-44128. doi: 10.18632/​oncotarget.9859.</​wrap>​ <wrap lo>​Oncotarget. 2016 Jul 12;​7(28):​44113-44128. doi: 10.18632/​oncotarget.9859.</​wrap>​
  
 De Angelis ML et al. \\ De Angelis ML et al. \\
-Cancer Stem Cell-Based Models of Colorectal Cancer Reveal Molecular Determinants of Therapy Resistance. \\+[[https://​www.ncbi.nlm.nih.gov/​pubmed/​26956206|Cancer Stem Cell-Based Models of Colorectal Cancer Reveal Molecular Determinants of Therapy Resistance.]] \\
 <wrap lo>Stem Cells Transl Med. 2016 Apr;​5(4):​511-23. doi: 10.5966/​sctm.2015-0214.</​wrap>​ <wrap lo>Stem Cells Transl Med. 2016 Apr;​5(4):​511-23. doi: 10.5966/​sctm.2015-0214.</​wrap>​
  
 Marziali G, Signore M et al. \\ Marziali G, Signore M et al. \\
-Metabolic/​Proteomic Signature Defines Two Glioblastoma Subtypes With Different Clinical Outcome. \\+[[https://​www.ncbi.nlm.nih.gov/​pubmed/​26857460|Metabolic/​Proteomic Signature Defines Two Glioblastoma Subtypes With Different Clinical Outcome.]] \\
 <wrap lo>Sci Rep. 2016 Feb 9;6:21557. doi: 10.1038/​srep21557.</​wrap>​ <wrap lo>Sci Rep. 2016 Feb 9;6:21557. doi: 10.1038/​srep21557.</​wrap>​
  
 Trono P et al. \\ Trono P et al. \\
-hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells. \\+[[https://​www.ncbi.nlm.nih.gov/​pubmed/​25961924|hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells.]] \\
 <wrap lo>​Oncogene. 2016 Feb 18;​35(7):​887-96. doi: 10.1038/​onc.2015.143. Epub 2015 May 11.</​wrap>​ <wrap lo>​Oncogene. 2016 Feb 18;​35(7):​887-96. doi: 10.1038/​onc.2015.143. Epub 2015 May 11.</​wrap>​
  
 Signore M et al. \\ Signore M et al. \\
-Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo. \\+[[https://​www.ncbi.nlm.nih.gov/​pubmed/​24810059|Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.]] \\
 <wrap lo>Cell Death Dis. 2014 May 8;5:e1223. doi: 10.1038/​cddis.2014.188.</​wrap>​ <wrap lo>Cell Death Dis. 2014 May 8;5:e1223. doi: 10.1038/​cddis.2014.188.</​wrap>​
  
 Forte S et al. \\ Forte S et al. \\
-Gene expression analysis of PTEN positive glioblastoma stem cells identifies DUB3 and Wee1 modulation in a cell differentiation model. \\+[[https://​www.ncbi.nlm.nih.gov/​pubmed/​24349068|Gene expression analysis of PTEN positive glioblastoma stem cells identifies DUB3 and Wee1 modulation in a cell differentiation model.]] \\
 <wrap lo>PLoS One. 2013 Dec 12;​8(12):​e81432. doi: 10.1371/​journal.pone.0081432.</​wrap>​ <wrap lo>PLoS One. 2013 Dec 12;​8(12):​e81432. doi: 10.1371/​journal.pone.0081432.</​wrap>​
  
 Sette G et al. \\ Sette G et al. \\
-EGFR inhibition abrogates leiomyosarcoma cell chemoresistance through inactivation of survival pathways and impairment of CSC potential. \\+[[https://​www.ncbi.nlm.nih.gov/​pubmed/​23056514|EGFR inhibition abrogates leiomyosarcoma cell chemoresistance through inactivation of survival pathways and impairment of CSC potential.]] \\
 <wrap lo>PLoS One. 2012;​7(10):​e46891. doi: 10.1371/​journal.pone.0046891.</​wrap>​ <wrap lo>PLoS One. 2012;​7(10):​e46891. doi: 10.1371/​journal.pone.0046891.</​wrap>​
  
 Francescangeli F et al. \\ Francescangeli F et al. \\
-Proliferation state and polo-like kinase1 dependence of tumorigenic colon cancer cells. \\+[[https://​www.ncbi.nlm.nih.gov/​pubmed/​22753241|Proliferation state and polo-like kinase1 dependence of tumorigenic colon cancer cells.]] \\
 <wrap lo>Stem Cells. 2012 Sep;​30(9):​1819-30. doi: 10.1002/​stem.1163.</​wrap>​ <wrap lo>Stem Cells. 2012 Sep;​30(9):​1819-30. doi: 10.1002/​stem.1163.</​wrap>​
  
 Signore M, Reeder KA. \\ Signore M, Reeder KA. \\
-Antibody validation by Western blotting. \\+[[https://​www.ncbi.nlm.nih.gov/​pubmed/​22081344|Antibody validation by Western blotting.]] \\
 <wrap lo>​Methods Mol Biol. 2012;​823:​139-55. doi: 10.1007/​978-1-60327-216-2_10.</​wrap>​ <wrap lo>​Methods Mol Biol. 2012;​823:​139-55. doi: 10.1007/​978-1-60327-216-2_10.</​wrap>​
  
 Napoletani D et al. \\ Napoletani D et al. \\
-Homologous control of protein signaling networks. \\+[[https://​www.ncbi.nlm.nih.gov/​pubmed/​21439301|Homologous control of protein signaling networks.]] \\
 <wrap lo>J Theor Biol. 2011 Jun 21;​279(1):​29-43. doi: 10.1016/​j.jtbi.2011.03.020.</​wrap>​ <wrap lo>J Theor Biol. 2011 Jun 21;​279(1):​29-43. doi: 10.1016/​j.jtbi.2011.03.020.</​wrap>​
  
 VanMeter A, Signore M, Pierobon M, Espina V, Liotta LA, Petricoin EF 3rd. \\ VanMeter A, Signore M, Pierobon M, Espina V, Liotta LA, Petricoin EF 3rd. \\
-Reverse-phase protein microarrays:​ application to biomarker discovery and translational medicine. \\+[[https://​www.ncbi.nlm.nih.gov/​pubmed/​17892368|Reverse-phase protein microarrays:​ application to biomarker discovery and translational medicine.]] \\
 <wrap lo>​Expert Rev Mol Diagn. 2007 Sep;​7(5):​625-33. Review.</​wrap>​ <wrap lo>​Expert Rev Mol Diagn. 2007 Sep;​7(5):​625-33. Review.</​wrap>​
  
 Spreafico F et al. \\ Spreafico F et al. \\
 Proteomics analysis of cerebrospinal fluid from children with Central Nervous System tumors identifies candidate proteins relating to tumor metastatic spread. \\ Proteomics analysis of cerebrospinal fluid from children with Central Nervous System tumors identifies candidate proteins relating to tumor metastatic spread. \\
-<wrap lo>​Oncotarget (submitted, second round of revision)</​wrap>​+<wrap lo em>​Oncotarget (submitted, second round of revision)</​wrap>​
  
 Manic G & Signore M et al. \\ Manic G & Signore M et al. \\
 CHK1-targeted therapy to deplete DNA replication-stressed,​ p53-deficient hyperdiploid colorectal cancer stem cells. \\ CHK1-targeted therapy to deplete DNA replication-stressed,​ p53-deficient hyperdiploid colorectal cancer stem cells. \\
-<wrap lo>Gut (submitted, second round of revision)</​wrap>​+<wrap lo em>Gut (submitted, second round of revision)</​wrap>​
  
 Haas TL et al. \\ Haas TL et al. \\
 Identification of Integrin Alpha 7 as Functional Marker and Potential Therapeutic Target in Glioblastoma Multiforme. \\ Identification of Integrin Alpha 7 as Functional Marker and Potential Therapeutic Target in Glioblastoma Multiforme. \\
-<wrap lo>Cell Stem Cell (submitted, second round of revision)</​wrap>​+<wrap lo em>Cell Stem Cell (submitted, second round of revision)</​wrap>​